Clinical Trials Logo

Advanced Breast Cancer clinical trials

View clinical trials related to Advanced Breast Cancer.

Filter by:

NCT ID: NCT00322348 Completed - Clinical trials for Advanced Breast Cancer

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of progression-free survival at 24 weeks. Secondary Objectives are to compare the safety and tolerability profile of ZOLADEX 10.8 mg and ZOLADEX 3.6 mg by assessment of adverse events (AEs)and to assess goserelin PK in Japanese and Caucasian participants who have received ZOLADEX 10.8 mg by assessment of goserelin plasma concentration time profiles Recruitment into the study has been permanently stopped as of 24 December 2007 due to slow recruitment. 98 (vs the planned 260) patients were randomised into the study and will be followed as per protocol for 2 years

NCT ID: NCT00313170 Completed - Clinical trials for Metastatic Breast Cancer

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

FINDER II
Start date: May 30, 2006
Phase: Phase 2
Study type: Interventional

This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.

NCT ID: NCT00305448 Completed - Clinical trials for Metastatic Breast Cancer

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

FINDER I
Start date: March 2006
Phase: Phase 2
Study type: Interventional

This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.

NCT ID: NCT00106145 Completed - Clinical trials for Advanced Breast Cancer

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Start date: April 2005
Phase: Phase 1
Study type: Interventional

An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.